Description

UBICAR TAB (1X10)

Indications

UBICAR TAB is primarily indicated for the treatment of metabolic acidosis in patients with chronic kidney disease (CKD) or those undergoing dialysis. It is also utilized in conditions where bicarbonate levels need to be restored, such as in certain cases of diabetic ketoacidosis or acute renal failure. The formulation helps to correct the acid-base balance in the body, promoting better overall metabolic function.

Mechanism of Action

The active ingredient in UBICAR TAB is sodium bicarbonate, which acts as a systemic alkalizing agent. When ingested, it dissociates in the gastrointestinal tract to release bicarbonate ions. These bicarbonate ions then enter the bloodstream, where they help to neutralize excess hydrogen ions, thereby increasing the pH of the blood. This action effectively counteracts acidosis and restores a more neutral acid-base balance in the body.

Pharmacological Properties

UBICAR TAB exhibits several pharmacological properties that make it effective in treating metabolic acidosis. The primary property is its ability to increase serum bicarbonate levels, which is crucial in maintaining the acid-base equilibrium. Additionally, sodium bicarbonate has a relatively rapid onset of action, typically within 30 minutes to 2 hours after administration. The duration of effect can vary, but it generally lasts for several hours, making it suitable for both acute and chronic management of acidosis.

Contraindications

UBICAR TAB should not be used in patients with known hypersensitivity to sodium bicarbonate or any of its components. It is also contraindicated in individuals with metabolic or respiratory alkalosis, as the administration of bicarbonate may exacerbate these conditions. Furthermore, patients with severe renal impairment or those who are unable to excrete bicarbonate effectively should avoid this medication, as it may lead to bicarbonate accumulation and subsequent alkalosis.

Side Effects

While UBICAR TAB is generally well-tolerated, some patients may experience side effects. Common side effects include gastrointestinal disturbances such as nausea, vomiting, and abdominal discomfort. Other potential side effects may include headache, flatulence, and increased thirst. In rare cases, excessive bicarbonate administration can lead to metabolic alkalosis, characterized by symptoms such as muscle twitching, hand tremors, and confusion. Patients should be monitored for these side effects, especially during the initiation of therapy or when adjusting dosages.

Dosage and Administration

The recommended dosage of UBICAR TAB varies based on the severity of the condition being treated and the patient’s individual response. For adults, the typical starting dose is 325 mg to 650 mg taken orally, one to four times daily, depending on the clinical situation and physician’s recommendations. It is important to take the tablets with a full glass of water to facilitate dissolution and absorption. Dosage adjustments may be necessary based on serum bicarbonate levels and overall clinical response. Patients are advised to follow their healthcare provider’s instructions closely regarding dosing schedules and adjustments.

Interactions

UBICAR TAB may interact with certain medications and substances. For instance, it can affect the absorption and efficacy of some drugs, including tetracycline antibiotics and iron supplements, due to altered gastric pH. Additionally, concurrent use of diuretics, particularly thiazide or loop diuretics, may increase the risk of electrolyte imbalances when combined with sodium bicarbonate. It is essential for patients to inform their healthcare providers about all medications they are taking to avoid potential interactions and ensure safe and effective use of UBICAR TAB.

Precautions

Patients using UBICAR TAB should be monitored closely for signs of metabolic alkalosis, especially those with pre-existing conditions that may predispose them to this complication. Caution is advised in patients with cardiovascular disease, as sodium bicarbonate can cause fluid retention and increase blood pressure. Additionally, individuals on a sodium-restricted diet should consider the sodium content of UBICAR TAB, as excessive sodium intake may lead to complications such as hypertension or edema. Regular monitoring of serum bicarbonate levels and electrolytes is recommended during treatment.

Clinical Studies

Clinical studies have demonstrated the efficacy of sodium bicarbonate in correcting metabolic acidosis in patients with chronic kidney disease. A study published in the Journal of the American Society of Nephrology found that sodium bicarbonate therapy improved metabolic acidosis and slowed the progression of kidney disease in patients with stage 4 CKD (DOI: 10.1681/ASN.2012030263). Another study highlighted the benefits of bicarbonate supplementation in patients undergoing dialysis, showing significant improvements in acid-base balance and overall metabolic health (DOI: 10.1056/NEJMoa1401345). These studies underscore the importance of UBICAR TAB in managing acidosis and its potential to improve patient outcomes.

Conclusion

UBICAR TAB (1X10) is an effective therapeutic option for managing metabolic acidosis in various clinical settings. Its mechanism of action as a systemic alkalizing agent helps to restore acid-base balance, making it a valuable treatment for patients with chronic kidney disease and other conditions associated with acidosis. While generally well-tolerated, it is essential to monitor for potential side effects and interactions with other medications. Patients should adhere to prescribed dosages and consult their healthcare providers for any concerns or questions regarding their treatment with UBICAR TAB.